The adaptor-related protein AP2 is a heterotetrameric complex consisting of α, β, μ, and σ subunits, which plays a crucial role in clathrin-mediated endocytosis (CME) and especially in the retrieval of synaptic vesicles at nerve terminals. 1 Interestingly, several stud- ies have elucidated that CME of plasma membrane proteins con- trols the neuronal surface expression of γ- aminobutyric acid and glutamate receptors involved in long-term plastic changes in neuro- transmission and excitatory/inhibitory balance.1 However, only five individuals with AP2M1 mutations associated with neurodevelop - mental disorders have been reported in the literature so far, 1,2 and the few clinical data available suggest that AP2M1 mutations cause a variable phenotype ranging from severe intellectual disability, autism spectrum disorder, and epilepsy to isolated global develop - mental delay (GDD). We report an individual carrying a novel de novo AP2M1 variant with attention- deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, and unexpected hemiplegic migraine (HM).

Mangano, G.D., Antona, V., Santangelo, G., Di Pasquale, G., Colella, J., Salpietro, V., et al. (2025). A novel de novo AP2M1 variant in a patient with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and unexpected hemiplegic migraine. HEADACHE, 65(8), 1497-1499 [10.1111/head.15017].

A novel de novo AP2M1 variant in a patient with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and unexpected hemiplegic migraine

Mangano G. D.;Antona V.;Mangano G. R.;
2025-01-01

Abstract

The adaptor-related protein AP2 is a heterotetrameric complex consisting of α, β, μ, and σ subunits, which plays a crucial role in clathrin-mediated endocytosis (CME) and especially in the retrieval of synaptic vesicles at nerve terminals. 1 Interestingly, several stud- ies have elucidated that CME of plasma membrane proteins con- trols the neuronal surface expression of γ- aminobutyric acid and glutamate receptors involved in long-term plastic changes in neuro- transmission and excitatory/inhibitory balance.1 However, only five individuals with AP2M1 mutations associated with neurodevelop - mental disorders have been reported in the literature so far, 1,2 and the few clinical data available suggest that AP2M1 mutations cause a variable phenotype ranging from severe intellectual disability, autism spectrum disorder, and epilepsy to isolated global develop - mental delay (GDD). We report an individual carrying a novel de novo AP2M1 variant with attention- deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, and unexpected hemiplegic migraine (HM).
2025
Settore PSIC-01/B - Neuropsicologia e neuroscienze cognitive
Settore MEDS-20/B - Neuropsichiatria infantile
Mangano, G.D., Antona, V., Santangelo, G., Di Pasquale, G., Colella, J., Salpietro, V., et al. (2025). A novel de novo AP2M1 variant in a patient with attention-deficit/hyperactivity disorder, oppositional defiant disorder, and unexpected hemiplegic migraine. HEADACHE, 65(8), 1497-1499 [10.1111/head.15017].
File in questo prodotto:
File Dimensione Formato  
Headache - 2025 - Mangano - A novel de novo AP2M1 variant in a patient with attention‐deficit hyperactivity disorder .pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 150.11 kB
Formato Adobe PDF
150.11 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/698565
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact